Less than a week ago, almost nobody had heard the word Omicron.
By Friday, governments around the world were restricting travel from southern Africa, stock markets were falling, scientists were racing to understand a heavily mutated coronavirus variant and the World Health Organization had classified it as a Variant of Concern.
There is still an enormous amount we do not know. We do not yet know with confidence whether Omicron causes more severe disease than previous variants. We do not know exactly how effectively it escapes immunity produced by vaccination or previous infection. Scientists are concerned by the number and location of its mutations, particularly in the spike protein, but concern is not the same thing as evidence that the worst possibilities will occur.
That uncertainty should matter.
Political systems, however, rarely have the luxury of waiting until uncertainty disappears.
Governments have to make decisions now.
Britain has restricted travel from several southern African countries. The European Union has moved towards similar restrictions. The United States will impose restrictions on travellers from South Africa and several neighbouring countries beginning Monday. Israel has gone even further, announcing restrictions on entry by foreigners.
From the perspective of a government responsible for protecting its population, the logic is understandable. If there is a possibility that a new variant spreads faster or evades existing immunity, delaying its arrival even briefly could buy scientists and hospitals valuable time.
But there is something deeply uncomfortable about what has happened this week.
South African scientists identified a potential threat and rapidly told the world about it.
The world’s immediate response was to isolate southern Africa.
That may be epidemiologically defensible.
Politically, it creates a terrible incentive.
Imagine you are a health official in another country several months from now. Your laboratories discover an unusual cluster of infections containing a potentially dangerous new variant. You know that reporting it immediately is the scientifically responsible thing to do.
You also know what happened to South Africa.
Flights were cancelled. Tourists disappeared. Governments imposed restrictions. Financial markets reacted. Your country’s economy may suffer simply because your scientists were good enough to discover the problem first.
Now reporting is no longer costless.
That is dangerous.
Pandemic surveillance depends on countries sharing information quickly. A virus does not respect national borders, so one country’s epidemiological information becomes a global public good. When South Africa sequences viral genomes and identifies a concerning mutation, the information benefits India, Britain, America and everyone else.
But the cost of producing and revealing that information can fall disproportionately on South Africa.
This is another collective-action problem.
The world wants every country to disclose dangerous variants immediately.
Each individual country may have an incentive to avoid becoming the country associated with the dangerous variant.
If international policy makes honesty economically expensive, we should not be surprised if future governments become less enthusiastic about being honest.
That does not mean South Africa necessarily concealed anything before this week, nor does it mean another country would deliberately hide a variant. The point is about institutional design.
Good systems should not depend entirely on governments choosing the globally responsible action when that action predictably harms their own national interest.
They should make cooperation rational.
At the moment, we may be doing the opposite.
There is also a basic scientific problem with calling Omicron the “South African variant”.
South Africa reported it.
That does not necessarily mean the variant originated there.
Those are completely different statements.
South Africa has sophisticated genomic surveillance. A country that looks harder for variants may discover them earlier than a country doing less sequencing.
This creates a strange statistical problem: better surveillance can make a country appear to have more problems because it is better at detecting them.
The same phenomenon occurs in many areas of government.
A country that aggressively investigates corruption may report more corruption cases than a country that barely investigates corruption. That does not automatically mean the first country is more corrupt.
A government that tests extensively for disease may report more cases than a government that barely tests.
Measurement changes what becomes visible.
We therefore have to be careful not to confuse where something was detected with where something began.
The WHO’s decision to name variants using Greek letters rather than geographic labels is partly intended to prevent exactly this kind of stigma.
Yet policy can recreate the stigma even if terminology avoids it.
If restrictions focus primarily on southern African countries because South African scientists reported Omicron, the economic association remains.
The travel restrictions themselves deserve more careful analysis too.
The argument for them is not necessarily that borders can permanently stop Omicron.
That may already be impossible.
Cases connected to the variant have been identified outside southern Africa, and modern international travel makes complete containment extraordinarily difficult.
The more realistic objective is buying time.
That distinction matters.
A policy can fail to prevent something permanently and still succeed if delay has value.
If travel restrictions delay widespread transmission by two weeks, scientists gain two weeks to study vaccine effectiveness. Governments gain two weeks to increase sequencing. Pharmaceutical companies gain two weeks to evaluate whether vaccines need modification. Hospitals gain two weeks to prepare.
Time itself can be a policy outcome.
But if restrictions do not meaningfully delay transmission, their costs become much harder to justify.
Southern African economies lose tourism and business travel. Families are separated. Airlines lose revenue. People who had planned journeys suddenly face uncertainty.
Again, policy should be judged against a counterfactual.
Not “did Omicron eventually spread despite restrictions?”
The relevant question is “did restrictions slow its spread enough to justify their costs?”
We will not know the answer immediately.
This is another reason pandemic policymaking is so difficult. Governments have to act before the evidence necessary to evaluate the action exists.
There is an asymmetry in political criticism too.
Imagine a government imposes travel restrictions and Omicron turns out to be relatively manageable. Critics say it overreacted.
Now imagine the government waits for evidence and Omicron turns out to be extremely dangerous. Critics ask why it ignored the warning.
The government therefore has to make decisions under uncertainty where one type of mistake is politically and medically much more visible than the other.
This encourages precaution.
Sometimes appropriately.
But precaution has costs too.
The phrase “better safe than sorry” sounds sensible until applied without limits. Almost any restriction can be defended by saying there is some possibility of catastrophic harm.
Policy therefore needs to consider probability as well as severity.
A one-in-two chance of enormous harm is different from a one-in-a-million chance of the same harm.
At the moment, Omicron’s probabilities are exactly what scientists are trying to establish.
There is another issue exposed by Omicron that may be much more important than travel restrictions: global vaccination inequality.
South Africa’s vaccination rate remains substantially below those of wealthy Western countries. Across Africa, vaccination coverage is much lower still.
There are many reasons for this, and it would be too simple to describe the problem entirely as rich countries hoarding vaccines. Supply constraints, distribution systems, healthcare infrastructure and vaccine hesitancy all matter differently across countries.
But wealthy states unquestionably secured enormous quantities of vaccine early.
Some are now administering booster doses while large populations elsewhere have not received first doses.
That is morally uncomfortable.
It may also be strategically irrational.
A virus replicates when it infects people.
Every infection creates another opportunity for mutation.
Most mutations are insignificant. Some may eventually alter transmissibility or immune escape.
That means uncontrolled transmission anywhere can create risks everywhere.
Vaccinating somebody in another country can therefore provide benefits to citizens at home.
This breaks the normal distinction between foreign aid and national interest.
A vaccine donated abroad is not necessarily charity.
It can be self-protection.
This is where the politics becomes frustrating.
Governments naturally prioritise their own citizens. If an Indian government has vaccines available while Indians remain unvaccinated, giving those doses abroad would be politically difficult. The same applies to Britain or America.
From the perspective of each government individually, national priority is rational.
From the perspective of the world collectively, everyone competing to vaccinate low-risk citizens with third doses while vulnerable people elsewhere remain completely unvaccinated may allow transmission to continue at levels that increase risks for everyone.
Again: individually rational behaviour can produce a collectively worse outcome.
COVID seems almost designed to expose the weaknesses of political systems organised primarily around national borders.
Viruses operate globally.
Political accountability remains national.
The same problem appeared with climate change in Glasgow. Emissions anywhere affect people everywhere, yet governments bear costs domestically and answer to domestic voters.
Pandemics have the same structure but operate much faster.
A tonne of carbon emitted today affects climate over decades.
A variant detected today can appear on another continent within days.
The time available for cooperation is dramatically shorter.
Omicron also raises questions about intellectual property and vaccine manufacturing. India and South Africa have pushed for waiving certain intellectual-property protections relating to COVID technologies at the World Trade Organization, arguing that extraordinary circumstances justify expanding access to production.
Pharmaceutical companies and some governments argue that intellectual property is not the principal bottleneck and that vaccine manufacturing requires specialised knowledge, equipment, inputs and quality control that cannot simply be created by removing patents.
Both points contain truth.
A patent waiver does not magically construct a vaccine factory.
But intellectual-property rules can still affect who is legally able to produce technology and under what conditions.
The more useful question is therefore not “patents or no patents?”
It is: what combination of licensing, technology transfer, manufacturing investment and intellectual-property reform increases global vaccine production fastest without destroying incentives to develop future medicines?
That is a much less politically satisfying question because it does not fit neatly into “greedy pharmaceutical companies” versus “governments attacking innovation”.
But public policy rarely improves when complexity is forced into slogans.
There is also a question of reciprocity for countries providing global health information.
If South Africa’s surveillance system produces information that benefits everyone, perhaps the international community should compensate rather than punish that contribution.
That does not necessarily mean eliminating every temporary travel restriction. Governments may still decide restrictions are necessary.
But countries affected by those measures could receive additional financial assistance, vaccine supplies, testing resources or other support.
The principle would be straightforward:
If transparency creates a global benefit but imposes a local cost, share the cost.
That changes incentives.
It tells governments that discovering bad news will not leave them alone with the economic consequences of reporting it.
This principle extends beyond pandemics.
Countries under-report problems when disclosure is punished.
Banks hide losses when admitting losses triggers collapse.
Companies conceal safety failures when disclosure creates enormous liability.
Governments manipulate economic statistics when bad numbers create political costs.
Transparency is often treated as a moral characteristic: honest institutions tell the truth.
But transparency is also an incentive problem.
If we want people and governments to reveal damaging information, systems should make revealing it less costly than hiding it.
This is perhaps the most important political lesson from Omicron so far.
We do not yet know whether this variant will transform the pandemic.
It might.
It might not.
Scientists need time and data.
But the political response has already revealed something about the international system.
We say we want early warnings.
Then we punish the country that sounds the alarm.
That contradiction is dangerous.
The South African government has strongly criticised the travel bans, arguing that the country is effectively being penalised for advanced genomic sequencing and rapid transparency. That criticism deserves to be taken seriously even if individual governments still conclude that temporary restrictions are justified.
The two positions are not mutually exclusive.
Britain can rationally believe a temporary travel restriction protects its population.
South Africa can rationally believe being targeted for restrictions creates an unfair cost for providing information that benefits Britain.
The job of international institutions should be to reconcile those incentives.
Otherwise everyone behaves rationally and the global system behaves irrationally.
There is also a broader lesson here about uncertainty.
During the pandemic, political debate has repeatedly demanded certainty from science that science cannot provide.
Is the variant more transmissible?
Do vaccines still work?
Will hospitals be overwhelmed?
Scientists answer with probabilities, confidence intervals, incomplete datasets and statements that conclusions may change as evidence improves.
Politics prefers yes or no.
That mismatch creates distrust when scientific guidance changes.
But changing conclusions in response to new evidence is not evidence that science failed.
It is what evidence-based reasoning is supposed to look like.
The political failure occurs when governments present uncertain evidence as certainty because they believe citizens cannot tolerate ambiguity.
Then, when evidence changes, people conclude they were lied to.
Perhaps governments need to become better at saying:
We do not know yet. Here is what we know, here is what we fear, and here is why we are acting before we know more.
That is less reassuring.
It may be more trustworthy.
Right now, that is the most defensible position on Omicron.
We know it contains a large number of mutations.
We know it has spread rapidly in parts of southern Africa.
We know cases have already been detected elsewhere.
We know the WHO considers it concerning enough to designate it a Variant of Concern.
We do not yet know exactly how much more transmissible it is, how severe the disease it causes will be or how substantially it affects vaccine protection.
Policy therefore has to operate between ignorance and panic.
Temporary precautions may be justified.
Permanent conclusions are not.
And while governments study the variant, they should also study the incentive they have just created.
South Africa found something potentially dangerous and told everyone.
Within days, aircraft routes disappeared.
The next dangerous variant will emerge somewhere.
Maybe India.
Maybe Europe.
Maybe South America.
Maybe somewhere without South Africa’s sequencing capacity.
Wherever it appears, the entire world has an interest in learning about it as quickly as possible.
That means the country discovering it is providing everyone else with something extraordinarily valuable:
time.
We should be very careful about constructing an international system in which the price of giving the world that time is economic isolation.
Because the next government may look at what happened to South Africa this week and decide that being first to know is valuable.
Being first to tell everyone else may not be.
